Chelation therapy

Medical uses

Chelation therapy is the preferred medical treatment for metal poisoning, including acute mercury, iron (including in cases of sickle-cell disease and thalassemia),{{cite book

Chelating agents

There are a variety of common chelating agents with differing affinities for different metals, physical characteristics, and biological mechanism of action. For the most common forms of heavy metal intoxication – lead, arsenic, or mercury – a number of chelating agents are available. Dimercaptosuccinic acid (DMSA) has been recommended by poison control centers around the world for the treatment of lead poisoning in children. Other chelating agents, such as 2,3-dimercaptopropanesulfonic acid (DMPS) and alpha lipoic acid (ALA), are used in conventional and alternative medicine. Some common chelating agents are ethylenediaminetetraacetic acid (EDTA), 2,3-dimercaptopropanesulfonic acid (DMPS), and thiamine tetrahydrofurfuryl disulfide (TTFD). Calcium-disodium EDTA and DMSA are only approved for the removal of lead by the Food and Drug Administration while DMPS and TTFD are not approved by the FDA. These drugs bind to heavy metals in the body and prevent them from binding to other agents. They are then excreted from the body. The chelating process also removes vital nutrients such as vitamins C and E, therefore these must be supplemented.

The German Environmental Agency (Umweltbundesamt) listed DMSA and DMPS as the two most useful and safe chelating agents available.

Side effects

Chelation therapy, used to remove toxic metals such as lead, arsenic, or mercury from the body, carries a range of potential side effects. When administered appropriately under medical supervision, side effects may include dehydration, hypocalcemia (low calcium levels), renal impairment, elevated liver enzymes, electrolytes imbalances, and allergic reactions. The loss of essential dietary elements such as zinc, magnesium, and iron is common, especially with prolonged therapy, potentially leading to fatigue, weakened immunity, or neurological disturbances.

In contrast, inappropriate or non-medical use for example, in unapproved treatments for autism or cardiovascular disease - has been associated with serious complications, including severe hypocalcemia, neurodevelopmental disorders, and even death**.** Notably, disodium EDTA had been linked to fatal outcome when used incorrectly, such as through rapid IV administration.For these reasons, regulating authorities like FDA, CDC strongly discourage off label or unsupervised use of chelation agents.

Use in alternative medicine

In alternative medicine, some practitioners claim chelation therapy can treat a variety of ailments, including heart disease and autism. There has been scientific evidence that chelation therapy for heart disease is modestly successful. However, there is no proof that chelation therapy is effective for behavioral disorders such as autism. Chelation therapy prior to heavy metal testing can artificially raise urinary heavy metal concentrations ("provoked" urine testing) and lead to inappropriate and unnecessary treatment. The American College of Medical Toxicology and the American Academy of Clinical Toxicology warn the public that chelating drugs used in chelation therapy may have serious side effects, including liver and kidney damage, blood pressure changes, allergies and in some cases even death of the patient.

Cancer

The American Cancer Society says of chelation therapy: "Available scientific evidence does not support claims that it is effective for treating other conditions such as cancer. Chelation therapy can be toxic and has the potential to cause kidney damage, irregular heartbeat, and even death."

Cardiovascular disease

Chelation therapy for heart disease began in the 1950s after anecdotal reports that people treated with chelation for heavy metal poisoning had experienced an unexpected relief from symptoms of angina. In the 1980s-2000s, its practitioners estimated that between 100,000 and 200,000 Americans per year were undergoing chelation therapy for heart disease, at a cost of about $5,000 per course of treatment.

The American College of Cardiology and the Mayo Clinic do not currently endorse chelation therapy for heart disease. However, a large-scale clinical study published in 2012 did find a modest benefit from chelation therapy in improving outcomes for patients with a prior heart attack.

In the 1990s and early 2000s, the weight of scientific evidence was against any benefit of chelation therapy for heart disease.

In 1998, the U.S. Federal Trade Commission (FTC) even charged a chelation-advocacy group, the so-called American College for Advancement in Medicine (ACAM), with making false or unsubstantiated claims when they promoted chelation therapy for heart disease on their website and on a brochure they published. In December 1998, the FTC announced that it had secured a consent agreement barring ACAM from making claims that chelation therapy is effective against atherosclerosis or any other disease of the circulatory system.

However, in 2003-2012, the National Institutes of Health (NIH) sponsored a $30 million controlled trial of chelation therapy, conducted by their National Center for Complementary and Alternative Medicine (NCCAM). This was known as the Trial to Assess Chelation Therapy or TACT. In contrast to prior controlled studies that had produced negative findings, the TACT trial found that chelation therapy modestly improves outcomes for patients with a prior heart attack or history of heart attacks, and markedly improves outcomes if the patients were also diabetic.

In the leadup to the TACT trial, NCCAM Director Stephen E. Straus cited the "widespread use of chelation therapy in lieu of established therapies, the lack of adequate prior research to verify its safety and effectiveness, and the overall impact of coronary artery disease" as factors motivating the trial. Patient enrollment was to be completed around July 2009 with final completion around July 2010, but enrollment in the trial was voluntarily suspended by organizers in September 2008 after the U.S. government's Office for Human Research Protections began investigating complaints such as inadequate informed consent. At the time of suspension, the trial was criticized for other methodological flaws, including being conducted by "fringe" clinicians, and lacking prior Phase I and II studies. The same critics claimed that previous controlled trials "found no evidence that chelation is superior to placebo for treatment of CAD [Coronary Artery Disease] or PVD [Peripheral Vascular Disease]," making the trial "unethical, dangerous, pointless, and wasteful." However, the American College of Cardiology supported the trial.

The final results of the TACT trial were published in November 2012. The study enrolled 1708 patients who were in stable condition, at least 50 years old, and had had a prior heart attack. The patients were divided into two groups, receiving chelation therapy by infusions of disodium EDTA, or receiving normal recommended therapy including statins and aspirin. The study found an 18% reduction in heart events (death, another heart attack, stroke, stenting or bypass, and hospitalization for heart pains) in the patients receiving chelation therapy. And in patients with diabetes mellitus, there was a 41% reduction in clinical events, including a 43% reduction in deaths over 5 years. However, the results barely achieved statistical significance.

An editorial published in the Journal of the American Medical Association said that "the study findings may provide novel hypotheses that merit further evaluation to help understand the pathophysiology of secondary prevention of vascular disease." Critics of the study characterized it as showing no support for the use of chelation therapy in coronary heart disease, particularly the claims that chelation reduces the need for coronary bypass surgeries.

After the TACT study, further controlled studies in 2015-2022 concluded with cautious endorsements of chelation therapy for heart disease, particularly in patients with diabetes mellitus and prior heart attacks. However, an attempt to replicate the results of the TACT trial in diabetics with prior heart attacks failed to find any benefit.

Autism

Main article: Thiomersal controversy

Quackwatch says that autism is one of the conditions for which chelation therapy has been falsely promoted as effective, and practitioners falsify diagnoses of metal poisoning to trick parents into having their children undergo the risky process. , up to 7% of children with autism worldwide had been subjected to chelation therapy. The death of two children in 2005 was caused by the administration of chelation treatments, according to the American Center for Disease Control. One of them had autism. Parents either have a doctor use a treatment for lead poisoning, or buy unregulated supplements, in particular DMSA and lipoic acid. There is little to no credible scientific research that supports the use of chelation therapy for the effective treatment of autism.

Deaths from chelation therapy

In August 2005, a five-year-old boy with autism died while undergoing chelation therapy. Only the three-year-old girl had been found to have an elevated blood lead level and resulting low iron levels and anemia, which is the conventional medical cause for administration of chelation therapy.

According to protocol, EDTA should not be used in the treatment of children. More than 30 deaths have been recorded in association with IV-administered disodium EDTA since the 1970s.

History

Chelation therapy can be traced back to the early 1930s, when Ferdinand Münz, a German chemist working for I.G. Farben, first synthesized ethylenediaminetetraacetic acid (EDTA). Munz was looking for a replacement for citric acid as a water softener. Chelation therapy itself began during World War II when chemists at the University of Oxford searched for an antidote for lewisite, an arsenic-based chemical weapon. The chemists learned that EDTA was particularly effective in treating lead poisoning.

Following World War II, chelation therapy was used to treat workers who had painted United States naval vessels with lead-based paints. Clarke subsequently administered chelation therapy to patients with angina pectoris and other occlusive vascular disease and published his findings in The American Journal of the Medical Sciences in December 1956. He hypothesized that "EDTA could dissolve disease-causing plaques in the coronary systems of human beings." In a series of 283 patients treated by Clarke et al. From 1956 to 1960, 87% showed improvement in their symptomatology. Other early medical investigators made similar observations of EDTA's role in the treatment of cardiovascular disease (Bechtel, 1956; Bessman, 1957; Perry, 1961; Szekely, 1963; Wenig, 1958: and Wilder, 1962). However, later systemic reviews found that chelation was no better than placebo in treating heart disease.

In the 1960s, a chelating agent known as "British Anti-Lewisite" (BAL) was modified into DMSA, a related dithiol with far fewer side effects. DMSA quickly replaced both BAL and EDTA as the primary treatment for lead, arsenic and mercury poisoning in the United States. Esters of DMSA have been developed which are reportedly more effective; for example, the monoisoamyl ester (MiADMSA) is reportedly more effective than DMSA at clearing mercury and cadmium. Research in the former Soviet Union led to the introduction of DMPS, another dithiol, as a mercury-chelating agent. The Soviets also introduced ALA, which is transformed by the body into the dithiol dihydrolipoic acid, a mercury- and arsenic-chelating agent. DMPS has experimental status in the United States, while ALA is a common nutritional supplement.

Since the 1970s, iron chelation therapy has been used as an alternative to regular phlebotomy to treat excess iron stores in people with haemochromatosis. Other chelating agents have been discovered. They all function by making several chemical bonds with metal ions, thus rendering them much less chemically reactive. The resulting complex is water-soluble, allowing it to enter the bloodstream and be excreted harmlessly.

In 1973, a group of practicing physicians created the Academy of Medical Preventics, later renamed the American College for Advancement in Medicine (ACAM). The academy trains and certifies physicians in the safe administration of chelation therapy. Members of the academy continued to use EDTA therapy for the treatment of vascular disease and developed safer administration protocols. However, in 1998 the U.S. Federal Trade Commission (FTC) pursued the ACAM, an organization that promotes "complementary, alternative and integrative medicine" over the claims made regarding the treatment of atherosclerosis in advertisements for EDTA chelation therapy. The FTC concluded that there was a lack of scientific studies to support these claims and that the statements by the ACAM were false. In 1999, the ACAM agreed to stop presenting chelation therapy as effective in treating heart disease, avoiding legal proceedings. In 2010 the U.S. Food and Drug Administration (FDA) warned companies who sold over-the-counter (OTC) chelation products and stated that such "products are unapproved drugs and devices and that it is a violation of federal law to make unproven claims about these products. There are no FDA-approved OTC chelation products."

References

References

1. (6 May 2013). "Chelation: Therapy or "Therapy"?". National Capital Poison Center.
2. (2008). "Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned". Medscape Journal of Medicine.
3. (1 November 2008). "Chelation Therapy". [[American Cancer Society]].
4. "Deaths Associated with Hypocalcemia from Chelation Therapy - Texas, Pennsylvania, and Oregon, 2003-2005".
5. [[Food and Drug Administration]] (FDA). (14 October 2010). "FDA issues warnings to marketers of unapproved 'chelation' products".
6. (2010-06-28). "Chelation in Metal Intoxication". International Journal of Environmental Research and Public Health.
7. (May 8, 2018). "Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia". The Cochrane Database of Systematic Reviews.
8. (2015-01-01). "26 - Medical Countermeasures—Chelation Therapy". Academic Press.
9. Chisolm, J.J. Jr.. (2000). "Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations". [[Clinical Toxicology.
10. Bridges, Sarah. (January 2006). "The promise of chelation".
11. Kommission Human-Biomonitoring des Umweltbundesamtes [Human Biomonitoring Committee of the Federal Environmental Agency (Federal Republic of Germany )]. (1999). "Bekanntmachung des Umweltbundesamtes Einsatz von Chelatbildnern in der Umweltmedizin? Stellungnahme der Kommission 'Human-Biomonitoring' des Umweltbundesamtes". Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.
12. (2008). "Katzung & Trevor's Pharmacology: Examination & Board Review". [[McGraw-Hill Education.
13. (2015). "Medical Countermeasures—Chelation Therapy". Elsevier.
14. Barceloux, Donald G.. (2008-01-02). "Medical Toxicology of Natural Substances". Wiley.
15. (2006-08-01). "Deaths Resulting From Hypocalcemia After Administration of Edetate Disodium: 2003-2005". Pediatrics.
16. (2005). "CDC Issues Recommendations for Lead Poisoning Prevention in Newly Arrived Refugee Children".
17. Ernst, E.. (2000). "Chelation therapy for coronary heart disease: An overview of all clinical investigations". American Heart Journal.
18. (30 August 2005). "Boy with autism dies during 'chelation therapy'". Behavior Analysis Association of Michigan.
19. (February 2013). "Five Things Physicians and Patients Should Question". American College of Medical Toxicology and American Academy of Clinical Toxicology.
20. David Rakel, ''Integrative Medicine'' 5th edition, Elsevier, 2023.
21. Squires, Sally. (17 December 1985). "Study Would Test Chelation's Claims". The Washington Post.
22. (April 7, 2024). "Chelation Therapy Does Not Improve Outcomes after Heart Attack: Infusions reduce lead levels but show no effect on clinical endpoints". American College of Cardiology.
23. (18 March 2025). "Chelation therapy for heart disease: Does it work?". Mayo Clinic.
24. Andrew Pollack, [https://www.nytimes.com/2012/11/05/health/chelation-therapy-shows-slight-benefit-in-heart-disease-clinical-trial.html "Much-Debated Treatment for Heart Disease Shows Slight Benefit in Clinical Trial"], ''The New York Times'', Nov. 4, 2012.
25. Ernst, E.. (1997). "Chelation therapy for peripheral arterial occlusive disease: A systematic review". [[Circulation (journal).
26. (2005). "EDTA chelation therapy for cardiovascular disease: A systematic review". [[BMC journals.
27. Federal Trade Commission. (8 December 1998). "Medical Association Settles False Advertising Charges Over Promotion of 'Chelation Therapy'".
28. Lamas, G.A., et al. [https://jamanetwork.com/journals/jama/fullarticle/1672238 "Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial"]. ''JAMA'' 309.12 (2013): 1241-1250.
29. (2014). "The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT)". CircoutComes.
30. Lamas, Gervasio. (August 2013). "Trial to Assess Chelation Therapy (TACT)". [[United States National Library of Medicine.
31. (7 August 2002). "NIH Launches Large Clinical Trial on EDTA Chelation Therapy for Coronary Artery Disease". (NIH).
32. (March 2007). "Questions and Answers: The NIH Trial of EDTA Chelation Therapy for Coronary Artery Disease". [[National Center for Complementary and Alternative Medicine]] (NCCAM), [[National Institutes of Health]], [[United States Department of Health and Human Services.
33. (26 September 2008). "U.S. government probes chelation-heart disease study". CBC.
34. Jones, Valerie. (2009-07-09). "NIH Awards $30 Million Research Dollars To Convicted Felons: Cliff's Notes Version". [[Science-Based Medicine (website).
35. (2013). "Evaluation of the Trial to Assess Chelation Therapy (TACT): The Scientific Process, Peer Review, and Editorial Scrutiny". JAMA.
36. Atwood, Kimball. (4 November 2012). "The Trial to Assess Chelation Therapy: Equivocal as Predicted". [[Science-Based Medicine (website).
37. Gorski, David. (5 November 2012). "The result of the Trial to Assess Chelation Therapy (TACT): As underwhelming as expected". [[Science-Based Medicine (website).
38. (4 November 2012). "Chelation therapy doesn't alter quality of life in heart attack patients". [[American Heart Association]].
39. (2022). "Chelation Therapy in Patients with Cardiovascular Disease: A Systematic Review". Journal of the American Heart Association.
40. (2015). "Chelation Therapy". Circulation.
41. Lamas, G.A., et al. [https://jamanetwork.com/journals/jama/fullarticle/2822472 "Edetate disodium–based chelation for patients with a previous myocardial infarction and diabetes: TACT2 randomized clinical trial"]. ''JAMA'' 332.10 (2024): 794-803.
42. (15 May 2004). "Why Chelation Therapy Should Be Avoided". [[Quackwatch]].
43. Stokstad, E.. (2008). "Stalled trial for autism highlights dilemma of alternative treatments". Science.
44. (February 3, 2006). "FDA links child deaths to chelation therapy". Associated Press.
45. "Aspies For Freedom". [[Aspies For Freedom]].
46. (2007). "Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism". [[Pediatric Clinics of North America]].
47. (2013). "Chelation treatment for autism spectrum disorders: A systematic review". [[Research in Autism Spectrum Disorders]].
48. Blakeslee, Sandra. (19 May 2004). "Panel finds no evidence to tie autism to vaccines". [[The New York Times.
49. (2012). "Efficacy of DMSA therapy in a sample of Arab children with autistic spectrum disorder". Mædica.
50. (2009). "Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part B - Behavioral results". BMC Clinical Pharmacology.
51. (2009). "The severity of autism is associated with toxic metal body burden and red blood cell glutathione levels". Journal of Toxicology.
52. (2009). "Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A - Medical results". BMC Clinical Pharmacology.
53. (2008). "Pediatric fatality secondary to EDTA chelation". [[Clinical Toxicology]].
54. (2006). "Deaths associated with hypocalcemia from chelation therapy - Texas, Pennsylvania, and Oregon, 2003-2005". [[Centers for Disease Control and Prevention]].
55. Drugs, Committee on. (1995-07-01). "Treatment Guidelines for Lead Exposure in Children". Pediatrics.
56. Van der Schaar, Peter J.. (January 2014}}{{Full citation needed). "Textbook of Clinical Metal Toxicology". International Board of Clinical Metal Toxicology.
57. "Chemistry in its element: compounds". Royal Society of Chemistry.
58. (2002). "Inhibition of Warfarin Anticoagulation Associated with Chelation Therapy". Wiley.
59. (1988). "EDTA Chelation Therapy in Chronic Degenerative Disease". Medical Hypotheses.
60. Lewin, M R. (1997). "Chelation therapy for cardiovascular disease. Review and commentary.". Tex Heart Inst J.
61. (2005). "Strategies for safe and effective therapeutic measures for chronic arsenic and lead poisoning". Japan Society for Occupational Health.
62. (1 November 2007). "Hemochromatosis for healthcare professionals". Division of Nutrition and Physical Activity, National Center for Chronic Disease Prevention and Health Promotion, [[Centers for Disease Control and Prevention]], [[United States Department of Health and Human Services.
63. Hoffman, Ronald L.. (February 2014). "The facts and fictions of chelation therapy". The Clinical Advisor.
64. (13 July 1999). "American College for Advancement in Medicine: Case Timeline". [[Federal Trade Commission]] (FTC).
65. (12 January 1998). "Attachment A".